Harrow (HROW) Total Liabilities (2010 - 2026)
Harrow's (HROW) quarterly Total Liabilities came in at $391.2 million in Q1 2026, up 26.98% year-on-year from $308.1 million in Q1 2025, and up 12.61% quarter-over-quarter from $347.4 million in Q4 2025.
Harrow (HROW) Total Liabilities (2010 - 2026) Analysis & Trends
Harrow's Total Liabilities history runs 17 years deep, the most recent figure standing at $391.2 million for Q1 2026.
- On a quarterly basis, Total Liabilities rose 26.98% year-over-year to $391.2 million in Q1 2026; TTM through Mar 2026 was $391.2 million, a 26.98% increase from a year earlier, with the FY2025 full-year figure at $347.4 million, up 8.67% from the prior year.
- Total Liabilities grew to $391.2 million in Q1 2026 per HROW's latest filing, from $347.4 million in the prior quarter.
- Across five years, Total Liabilities topped out at $391.2 million in Q1 2026 and bottomed at $87.9 million in Q1 2022.
- The 5-year median for Total Liabilities is $241.8 million (2023), against an average of $236.2 million.
- Across the five-year window, Total Liabilities jumped 209.56% in 2022 and increased 7.65% in 2025, its largest moves.
- Year by year, Total Liabilities stood at $130.1 million in 2022, then soared by 85.77% to $241.8 million in 2023, then soared by 32.23% to $319.7 million in 2024, then climbed by 8.67% to $347.4 million in 2025, then increased by 12.61% to $391.2 million in 2026.
- Per Business Quant, the three latest HROW Total Liabilities figures stand at $391.2 million (Q1 2026), $347.4 million (Q4 2025), and $316.4 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Haleon | 87.22 Bn | 85.35 Bn | - | 21.48 Bn |
| 2 | Teva Pharmaceutical Industries | 39.60 Bn | 35.87 Bn | 1.97 Bn | 31.81 Bn |
| 3 | Zoetis | 31.46 Bn | 29.52 Bn | 1.62 Bn | 11.92 Bn |
| 4 | Takeda Pharmaceutical | 26.49 Bn | 22.44 Bn | 4.39 Bn | 51.53 Bn |
| 5 | United Therapeutics | 23.03 Bn | 20.88 Bn | 648.10 Mn | 813.10 Mn |
| 6 | Universe Pharmaceuticals | 23.03 Bn | -10.56 Bn | - | 13.17 Bn |
| 7 | Viatris | 20.90 Bn | 19.09 Bn | 1.16 Bn | 22.18 Bn |
| 8 | Neurocrine Biosciences | 17.50 Bn | 16.19 Bn | 800.70 Mn | 1.50 Bn |
| 9 | Elanco Animal Health | 12.33 Bn | 11.91 Bn | 785.00 Mn | 6.72 Bn |
| 10 | Harrow | 1.56 Bn | 1.47 Bn | 27.05 Mn | 391.19 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 391.19 Mn |
| Dec 31, 2025 | 347.39 Mn |
| Sep 30, 2025 | 316.41 Mn |
| Jun 30, 2025 | 295.73 Mn |
| Mar 31, 2025 | 308.07 Mn |
| Dec 31, 2024 | 319.67 Mn |
| Sep 30, 2024 | 293.92 Mn |
| Jun 30, 2024 | 248.45 Mn |
| Mar 31, 2024 | 235.33 Mn |
| Dec 31, 2023 | 241.75 Mn |
| Sep 30, 2023 | 210.66 Mn |
| Jun 30, 2023 | 201.94 Mn |
| Mar 31, 2023 | 195.97 Mn |
| Dec 31, 2022 | 130.14 Mn |
| Sep 30, 2022 | 98.13 Mn |
| Jun 30, 2022 | 92.67 Mn |
| Mar 31, 2022 | 87.86 Mn |
| Dec 31, 2021 | 87.40 Mn |
| Sep 30, 2021 | 86.57 Mn |
| Jun 30, 2021 | 84.12 Mn |